Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP929012.RA_X6oNmcMkG7pMN2k6OPdAJTEKt6VfCTma7k_LxLZc5A130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP929012.RA_X6oNmcMkG7pMN2k6OPdAJTEKt6VfCTma7k_LxLZc5A130_assertion type Assertion NP929012.RA_X6oNmcMkG7pMN2k6OPdAJTEKt6VfCTma7k_LxLZc5A130_head.
- NP929012.RA_X6oNmcMkG7pMN2k6OPdAJTEKt6VfCTma7k_LxLZc5A130_assertion description "[We conducted an international, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of an anti-interleukin-5 monoclonal antibody, mepolizumab, in patients with the hypereosinophilic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP929012.RA_X6oNmcMkG7pMN2k6OPdAJTEKt6VfCTma7k_LxLZc5A130_provenance.
- NP929012.RA_X6oNmcMkG7pMN2k6OPdAJTEKt6VfCTma7k_LxLZc5A130_assertion evidence source_evidence_literature NP929012.RA_X6oNmcMkG7pMN2k6OPdAJTEKt6VfCTma7k_LxLZc5A130_provenance.
- NP929012.RA_X6oNmcMkG7pMN2k6OPdAJTEKt6VfCTma7k_LxLZc5A130_assertion SIO_000772 18344568 NP929012.RA_X6oNmcMkG7pMN2k6OPdAJTEKt6VfCTma7k_LxLZc5A130_provenance.
- NP929012.RA_X6oNmcMkG7pMN2k6OPdAJTEKt6VfCTma7k_LxLZc5A130_assertion wasDerivedFrom befree-20140225 NP929012.RA_X6oNmcMkG7pMN2k6OPdAJTEKt6VfCTma7k_LxLZc5A130_provenance.
- NP929012.RA_X6oNmcMkG7pMN2k6OPdAJTEKt6VfCTma7k_LxLZc5A130_assertion wasGeneratedBy ECO_0000203 NP929012.RA_X6oNmcMkG7pMN2k6OPdAJTEKt6VfCTma7k_LxLZc5A130_provenance.